Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip M Potter

Showing results (51-60 of 87) with videos related to

Pageof 9
Sort By:
Molecular Cancer Therapeutics|November 18, 2003
Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studiesKyoung Jin P Yoon, Erik J Krull, Christopher L Morton, et al.
Cancer Research|October 30, 2003
A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38Hilde Stubdal, Noah Perin, Marilyn Lemmon, et al.
Biochemical Pharmacology|September 14, 2010
Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11M Jason Hatfield, Lyudmila Tsurkan, Michael Garrett, et al.
Chemico-Biological Interactions|February 20, 2016
Carboxylesterases: General detoxifying enzymesM Jason Hatfield, Robyn A Umans, Janice L Hyatt, et al.
Bioorganic & Medicinal Chemistry|July 8, 2011
Requirements for mammalian carboxylesterase inhibition by substituted ethane-1,2-dionesElizabeth I Parkinson, M Jason Hatfield, Lyudmila Tsurkan, et al.
Molecular Cancer Therapeutics|July 5, 2006
Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapyK Jin Yoon, Jianjun Qi, Joanna S Remack, et al.
Cancer Research|August 3, 2005
Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecanEdyta Tyminski, Stanley Leroy, Kinya Terada, et al.
Bioorganic & Medicinal Chemistry|April 3, 2007
Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzilsLatorya D Hicks, Janice L Hyatt, Teri Moak, et al.
Molecular Therapy. Nucleic Acids|August 8, 2013
Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with ProdrugsKazue Kasai, Hiroshi Nakashima, Fang Liu, et al.
Journal of Medicinal Chemistry|November 26, 2010
Structure-activity relationships of substituted 1-pyridyl-2-phenyl-1,2-ethanediones: potent, selective carboxylesterase inhibitorsBrandon M Young, Janice L Hyatt, David C Bouck, et al.
Pageof 9

Showing results (51-60 of 87) with videos related to

Sort By:
Pageof 9
Molecular Cancer Therapeutics|November 18, 2003
Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studiesKyoung Jin P Yoon, Erik J Krull, Christopher L Morton, et al.
Cancer Research|October 30, 2003
A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38Hilde Stubdal, Noah Perin, Marilyn Lemmon, et al.
Biochemical Pharmacology|September 14, 2010
Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11M Jason Hatfield, Lyudmila Tsurkan, Michael Garrett, et al.
Chemico-Biological Interactions|February 20, 2016
Carboxylesterases: General detoxifying enzymesM Jason Hatfield, Robyn A Umans, Janice L Hyatt, et al.
Bioorganic & Medicinal Chemistry|July 8, 2011
Requirements for mammalian carboxylesterase inhibition by substituted ethane-1,2-dionesElizabeth I Parkinson, M Jason Hatfield, Lyudmila Tsurkan, et al.
Molecular Cancer Therapeutics|July 5, 2006
Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapyK Jin Yoon, Jianjun Qi, Joanna S Remack, et al.
Cancer Research|August 3, 2005
Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecanEdyta Tyminski, Stanley Leroy, Kinya Terada, et al.
Bioorganic & Medicinal Chemistry|April 3, 2007
Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzilsLatorya D Hicks, Janice L Hyatt, Teri Moak, et al.
Molecular Therapy. Nucleic Acids|August 8, 2013
Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with ProdrugsKazue Kasai, Hiroshi Nakashima, Fang Liu, et al.
Journal of Medicinal Chemistry|November 26, 2010
Structure-activity relationships of substituted 1-pyridyl-2-phenyl-1,2-ethanediones: potent, selective carboxylesterase inhibitorsBrandon M Young, Janice L Hyatt, David C Bouck, et al.
Pageof 9